Life sciences-focused venture firm Kurma Partners has secured Servier Laboratories for a third fund dedicated to early and incubation-stage therapeutics companies.

Venture capital firm Kurma Partners has achieved an oversubscribed €160m ($175m) close for its third therapeutics-focused fund with limited partners including pharmaceutical developer Servier Laboratories.

Research organisation Pasteur Institute, state-owned investment bank Bpifrance and its Investissements d’Avenir scheme, as well as the EU-owned European Investment Fund (EIF), German regional public development bank NRW.Bank and VC firm Idinvest Partners have also backed the fund.

Kurma Biofund III will typically invest $10.9m per deal, aiming to assemble a 12 to 15-strong portfolio…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?